Chugai Pharmaceutical signed an agreement with EpiVax to incorporate EpiVax’s ISPRI immunogenicity screening and deimmunization technology into Chugai’s drug development toolbox.
EpiVax has developed a web-based secure, interactive work environment for immunogenicity screening, the “interactive screening and protein re-engineering website”.
ISPRI can be used for high throughput screening of partial and complete sequences of biological (protein therapeutic) candidates.
Demmunization of Functional Therapeutics (DeFT), the approach used by EpiVax to redesign proteins, modifies the parts of the proteins that bind to human antigen presenting cells such as dendritic cells.
DeFT also takes into consideration Tregitopes (T regulatory epitopes), a unique EpiVax discovery that is associated with regulatory T cell induction.
The OptiMatrix tool is used in the optimization process, and T effector epitopes may be removed or Tregitopes may be reintroduced, depending on the protein sequences.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity